Baird’s Lineage Cell Therapeutics LCTX Stock Holding History

Baird’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$52K	Hold	13,010	–	–	﹤0.01%	1299
2014 Q4	$39K	Buy	+13,010	New	+$35.2K	﹤0.01%	1262

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baird's LCTX Position: Q1 2015 in Review

Baird held its Lineage Cell Therapeutics (LCTX) position steady in Q1 2015 at 13,010 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #1299.

Baird first reported a position in LCTX in Q4 2014 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold LCTX as of Q1 2015.

Baird held 13,010 shares of Lineage Cell Therapeutics worth $52K as of Q1 2015.
Baird left its Lineage Cell Therapeutics share count unchanged in Q1 2015.
Lineage Cell Therapeutics made up ﹤0.01% of Baird's portfolio in Q1 2015, its #1299 holding.
Baird first reported a position in Lineage Cell Therapeutics in Q4 2014 and has held it in 2 quarters since.
69 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.